CARDIOQUIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cardioquin, and when can generic versions of Cardioquin launch?
Cardioquin is a drug marketed by Pharm Res Assoc and is included in one NDA.
The generic ingredient in CARDIOQUIN is quinidine polygalacturonate. There are twenty-seven drug master file entries for this compound. Additional details are available on the quinidine polygalacturonate profile page.
Summary for CARDIOQUIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 9 |
Patent Applications: | 241 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CARDIOQUIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CARDIOQUIN
US Patents and Regulatory Information for CARDIOQUIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharm Res Assoc | CARDIOQUIN | quinidine polygalacturonate | TABLET;ORAL | 011642-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |